Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis
Current Oncology · 02.05.2024 · 31 (5) · 2598-2609
DOI: 10.3390/curroncol31050195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 02.05.2024. Verfasst von Dahlia Sano und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1500 East Medical Center Dr., University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Hodgkin Disease, Lymphoma, T-Cell, Peripheral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen (United States), Seagen Inc..
Abstract (Originalsprache)
Brentuximab vedotin (BV) monotherapy (BV-M) and combination (BV-C) therapies are safe and effective for classical Hodgkin lymphoma (cHL) and CD30-expressing peripheral T-cell lymphomas (PTCLs). Although the sample sizes have been small (12–29 patients), in clinical studies, response rates of 53–88% have been reported for BV retreatment in patients with an initial BV response. We evaluated the real-world characteristics and treatment patterns of cHL/PTCL patients who received BV and were retreated in the United States. Symphony Health Patient Claims (11/2013–1/2022) were retrospectively analyzed to identify cHL/PTCL patients treated with BV and retreated with BV-M, BV-C, or non-BV therapy. Patient characteristics were described by retreatment, and predictors of BV-M retreatment were identified. Among the cHL and PTCL patients treated with BV (n = 6442 and 2472, respectively), 13% and 12%, respectively, were retreated with BV; the median times from initial BV to BV-M retreatment were 5 and 7 months, respectively; and the numbers of BV-M retreatment doses were 4 and 5, respectively. Among cHL patients, the predictors of BV-M retreatment were age (18–39 vs. ≥60 years), sex (women vs. men), and previous stem cell transplantation (yes vs. no). Among PTCL patients, the only predictor of BV-M retreatment was systemic anaplastic large-cell lymphoma subtype (yes vs. no). Real-world data support clinical study results suggesting earlier BV treatment be considered, as BV retreatment may be an option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1500 East Medical Center Dr., University of Michigan, Ann Arbor, MI 48109, USA.
- Pfizer Inc., 21823 30th Drive SE, Bothell, WA 98021, USA.
- Genesis Research, 111 River St., Hoboken, NJ 07030, USA.
- Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene St. S9D04A, Baltimore, MD 21201, USA.
Förderung
- Seagen (United States)
- Seagen Inc.
Zitieren
APA
Sano, D., Liu, N., Knowles, S., MacEwan, J. P., Wang, S., Wogen, J., Yu, K. S., & Lee, S. T. (2024). Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis. Current Oncology, 31(5), 2598-2609. https://doi.org/10.3390/curroncol31050195
Vancouver
Sano D, Liu N, Knowles S, MacEwan JP, Wang S, Wogen J, et al. Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis. Current Oncology. 2024;31(5):2598-2609. doi:10.3390/curroncol31050195
BibTeX
@article{Sano2024,
author = {Sano, Dahlia and Liu, Nicholas and Knowles, Scott and MacEwan, Joanna P and Wang, Shu and Wogen, Jenifer and Yu, Kristina S and Lee, Seung Tae},
title = {Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {5},
pages = {2598--2609},
doi = {10.3390/curroncol31050195}
}
EUVIMED